ADXS - アドバクシス (Advaxis Inc.)

ADXSのニュース

   Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update  2019/12/20 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2019 and provides a business update. Fiscal Year 2019 and Recent Key Accomplishments Completed enrollment in the first and second dose levels in Part A of the ongoing Phase 1/2 trial evaluating ADXS-503, the Company’s ADXS-HOT drug candidate in
   Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference  2019/12/04 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer will present at the upcoming LD Micro Main Event Investor Conference being held from December 10-12, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Presentation Information: Date: Tuesday, December 10, 2019 Time:
   Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer  2019/12/03 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical study of ADXS-504, the Company’s ADXS-HOT drug candidate for prostate cancer. “We are pleased to announce continued clinical progress of our ADXS-HOT p
   The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J  2019/09/26 11:54:44 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 25.) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) ( announced lackadaisical efficacy data for pancreatic insufficiency drug) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Exagen Inc (NASDAQ: XGN ) (IPOed on Sep. 16) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Myovant Sciences Ltd (NYSE: MYOV ) Neon Therapeutics Inc (NASDAQ: NTGN ) Novelion Therapeutics Inc (NASDAQ: NVLN ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics Inc (NASDAQ: ONTX ) PDS Biotechnology Corp (NASDAQ: PDSB ) Plus Therapeutics Inc (NASDAQ: PSTV ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sophiris Bio Inc (NASDAQ: SPHS ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Tocagen Inc (NASDAQ: TOCA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Urogen Pharma Ltd (NASDAQ: URGN ) Vaxart Inc (NASDAQ: VXRT ) (announced positive topline results for an early-stage …
   The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug  2019/09/25 11:13:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 24) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Celgene Corporation (NASDAQ: CELG ) Natera Inc (NASDAQ: NTRA ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL )(announced positive results for the pediatric Phase 3 trial of dasiglucagon for severe hypoglycemia in diabetes) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 24) Aduro BioTech Inc (NASDAQ: ADRO ) Advaxis, Inc. (NASDAQ: ADXS ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) AnaptysBio Inc (NASDAQ: ANAB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Endologix, Inc. (NASDAQ: ELGX ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Fulcrum Therapeutics Inc (NASDAQ: FULC Innoviva Inc (NASDAQ: INVA ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Myovant Sciences Ltd (NYSE: MYOV ) Neon Therapeutics Inc (NASDAQ: NTGN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) ProQR Therapeutics NV (NASDAQ: PRQR ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) (priced its IPO on Sept. 13) Seelos Therapeutics Inc (NASDAQ: …
   Microcaps mostly among midday movers  2019-04-03
Gainers: Ocean Power Technologies (NASDAQ: OPTT ) +176% . Netshoes (Cayman) (NYSE: NETS ) +23% . Evogene (NASDAQ: EVGN ) +22% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +21% . DMC Global (NASDAQ: BOOM ) +19% . Fuel Tech (NASDAQ: FTEK ) +18% . VivoPower International (NASDAQ: VVP…
   GME and ADXS among premarket losers  2019-04-03
Fusion Connect (NASDAQ: FSNN ) -82% as audit problems prompt Chapter 11 analyst warning. More news on: Fusion Connect, Inc., Advaxis, Inc., AVEO Pharmaceuticals, Inc., Stocks on the move, Read more …
   Advaxis down 26% on pricing stock offering  2019-04-03
Advaxis (NASDAQ: ADXS ) prices its public offering of 2.5M common stock at a price of $4.00/share, for gross proceeds of ~ $10M. More news on: Advaxis, Inc., Healthcare stocks news, Stocks on the move, Read more …
   Advaxis Announces Pricing of Its Public Offering of Common Stock  2019-04-03 Business Wire
Advaxis, Inc. (Nasdaq: ADXS) (the Company) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a …

calendar